{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Cabiralizumab infusion interruptions"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"Cabiralizumab infusion modifications"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Nivolumab infusion interruptions"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Nivolumab infusion modifications"},{"categories":[{"measurements":[{"groupId":"OG000","value":"54"}]}],"title":"AEs leading to discontinuation of cabiralizumab or nivolumab"}],"denoms":[{"counts":[{"groupId":"OG000","value":"265"}],"units":"Participants"}],"description":"Safety: In the Phase 1b only, the incidence of treatment discontinuations, modifications, and interruptions due to adverse events.","groups":[{"description":"Participants received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG000","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received at least 1 dose of cabiralizumab and/or nivolumab at the RD of 4 mg/kg cabiralizumab + 3 mg/kg nivolumab.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug up to last dose; median (range) duration of exposure was 8 (2-108) weeks for cabiralizumab and 8 (2-156) weeks for nivolumab.","title":"Safety: Number of Participants With Treatment Discontinuations, Modifications, or Interruptions Due to Adverse Events (Phase 1b)","type":"PRIMARY","unitOfMeasure":"Participants"}